- Home
- ZNTL vs OBIO Comparison
ZNTL vs OBIO Comparison
Compare ZNTL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- OBIO
- Stock Information
- Founded
- ZNTL 2014
- OBIO 2017
- Country
- ZNTL United States
- OBIO United States
- Employees
- ZNTL N/A
- OBIO N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- ZNTL Health Care
- OBIO Health Care
- Exchange
- ZNTL Nasdaq
- OBIO Nasdaq
- Market Cap
- ZNTL 105.8M
- OBIO 124.9M
- IPO Year
- ZNTL 2020
- OBIO N/A
- Fundamental
- Price
- ZNTL $1.32
- OBIO $3.01
- Analyst Decision
- ZNTL Buy
- OBIO Strong Buy
- Analyst Count
- ZNTL 7
- OBIO 5
- Target Price
- ZNTL $8.60
- OBIO $14.20
- AVG Volume (30 Days)
- ZNTL 961.9K
- OBIO 243.1K
- Earning Date
- ZNTL 08-08-2025
- OBIO 08-11-2025
- Dividend Yield
- ZNTL N/A
- OBIO N/A
- EPS Growth
- ZNTL N/A
- OBIO N/A
- EPS
- ZNTL N/A
- OBIO N/A
- Revenue
- ZNTL $26,865,000.00
- OBIO $2,886,000.00
- Revenue This Year
- ZNTL N/A
- OBIO $20.47
- Revenue Next Year
- ZNTL N/A
- OBIO $11.45
- P/E Ratio
- ZNTL N/A
- OBIO N/A
- Revenue Growth
- ZNTL N/A
- OBIO 30.23
- 52 Week Low
- ZNTL $1.01
- OBIO $2.37
- 52 Week High
- ZNTL $5.70
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- ZNTL 47.15
- OBIO 47.82
- Support Level
- ZNTL $1.31
- OBIO $2.91
- Resistance Level
- ZNTL $1.54
- OBIO $3.48
- Average True Range (ATR)
- ZNTL 0.14
- OBIO 0.26
- MACD
- ZNTL -0.00
- OBIO -0.01
- Stochastic Oscillator
- ZNTL 31.36
- OBIO 28.78
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.